Istituto Clinico Humanitas

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 3 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Preclinical1

By Therapeutic Area

top 1

Oncology

1100%

R&D Momentum

47/100

Pipeline Velocity

19/100

Trial Completion Rate

86/100

Pipeline Concentration

100/100

Pipeline Freshness

29/100

Activity

Recent Activity

Last 14 days

Jul 8, 2026

Recruiting

Advanced Respiratory Monitoring for Safer Mechanical Ventilation in Patients Without Respiratory Failure

Earlier

Jun 26, 2026TrialIntra-operative Hypotension and Post-operative Lactate Level After Pancreatic-duodenectomy. A Prospective Multicenter Observational Study

Jun 26, 2026TrialRIght VEntricle Response to Major Lung Resection in VATS and Robotic Surgery (the RIVER-2 Study)

Jun 25, 2026TrialThe Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome: a Randomized Clinical Trial Within an Adaptive Platform Trial for Patients With Bloodstream Infections

Mar 25, 2026TrialMulticenter Retrospective International Study to Evaluate Outcomes and Safety of Patients Undergoing ERCP Using a Single-use Cholangioscope (SpyGlass DS II) and Single-use Duodenoscope (Exalt) - The MESE Study

Jun 16, 2023TrialStudy of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Dec 13, 2022TrialEvaluation Study of the Intestinal Microbiota and Quality of Life in Patients Suffering From IBS Treated With Bifidice

Dec 1, 2022TrialEvaluation of Efficacy, Safety and Patient' Satisfaction of Therapeutic Switch From Off-Steroids to Budesonide

4 more events

Dec 3, 2021TrialAnti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation

Jan 25, 2021TrialExploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity

Oct 19, 2020TrialImmune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT

Jun 19, 2020FDAReglan — GIMOTI

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

6 patent groups across drugs · Source: FDA Orange Book

DrugExpires

VeregenOct 2, 2026 Reglan5 patentsDec 22, 2029 ReglanMay 16, 2030 ReglanNov 17, 2038 ActhJul 18, 2041 Acth5 patentsOct 27, 2043

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Prostate Cancer

immune evaluation

Oncology

Prostate Cancer

immune evaluationPreclinical

Regulatory

Regulatory Timeline

19826 events

FDAJan 1

Acth — ACTHAR

Application NDA007504 (NDA)

FDAJan 1

Acth — ACTHAR GEL

Application NDA008372 (NDA)

FDAJan 1

Acth — CORTICOTROPIN

Application NDA010831 (NDA)

FDAJan 1

Acth — PURIFIED CORTROPHIN GEL

Application NDA008975 (NDA)

FDAJan 1

Reglan — REGLAN

Application NDA017862 (NDA)

FDAJan 1

Acth — ACTH

Application NDA008317 (NDA)

19831 event

FDAMar 25

Reglan — REGLAN

Application NDA018821 (NDA)

19871 event

FDAMay 5

Reglan — REGLAN

Application NDA017854 (NDA)

19881 event

FDADec 30

Oxistat — OXISTAT

Application NDA019828 (NDA)

19921 event

FDASep 30

Oxistat — OXISTAT

Application NDA020209 (NDA)

19952 events

FDADec 27

Arimidex — ARIMIDEX

Application NDA020541 (NDA)

FDAOct 4

Casodex — CASODEX

Application NDA020498 (NDA)

19981 event

FDAJun 4

Atacand — ATACAND

Application NDA020838 (NDA)

20051 event

FDAJun 10

Reglan — REGLAN ODT

Application NDA021793 (NDA)

20061 event

FDAOct 31

Veregen — VEREGEN

Application NDA021902 (NDA)

20091 event

FDASep 4

Reglan — METOZOLV ODT

Application NDA022246 (NDA)

20201 event

FDAJun 19

Reglan — GIMOTI

Application NDA209388 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)